COSM

0.483 -0.03 (-5.48%)

Cosmos Health Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website cosmosholdingsinc.com
Employees(FY) 102
ISIN US2214133058

Performance

-3.74%

-25.07%

-36.38%

-51.04%

-26.91%

YTD

-35.83%

Profile

Cosmos Health Inc. provides proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, cosmetics, nursery, health care and baby products, and medical devices. Its nutraceutical product portfolio includes Sky Premium Life and Mediterranation. The company serves wholesale pharmaceutical distributors and independent retail pharmacies. It operates in Greece, Germany, the United Kingdom, Italy, Denmark, Croatia, and Cyprus. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

1M 3M 6M YTD 1Y 2Y

Advanced Technical Analysis

Technical Analysis of COSM 2025-03-12

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 16 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 33 reinforcing the bearish outlook. This combination implies that the stock is currently facing significant selling pressure, with limit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of COSM

QualityGrowthMomentumValue4

Stock Rank

Recent News & Updates

2025-02-25 22:30
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates(Accesswire)
2025-02-17 19:30
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1(Accesswire)
2025-02-10 21:15
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market(Accesswire)
2025-02-10 00:30
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market(Accesswire)
2025-02-09 20:45
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations(Accesswire)
2025-02-06 21:00
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility(Accesswire)
2025-02-06 02:50
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar(Accesswire)
2025-02-04 22:05
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market(Accesswire)
2025-01-27 22:00
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow(Accesswire)
2025-01-27 02:50
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion(Accesswire)
2025-01-23 02:35
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait(Accesswire)
2025-01-21 19:00
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million(Accesswire)
2025-01-21 02:00
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days(Accesswire)
2025-01-13 20:41
Cosmos Health secures exclusive distribution agreement with Virax Biolabs(Yahoo Finance)
2025-01-12 20:20
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries(Accesswire)
2024-12-26 00:30
Cosmos Health Strengthens RandD Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology(Accesswire)
2024-12-26 00:30
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology(Accesswire)
2024-12-22 20:25
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000(Accesswire)
2024-11-25 20:30
Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price(Accesswire)
2024-11-25 20:30
Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price(Accesswire)
2024-11-17 19:00
Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets(Accesswire)
2024-11-14 21:20
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M(Accesswire)
2024-11-11 23:00
Cosmos Health Issues Letter to Shareholders(Accesswire)
2024-11-01 00:30
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%(Accesswire)
2024-09-24 21:25
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands(Accesswire)
2024-09-23 00:55
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins(Accesswire)
2024-09-22 21:00
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits(Accesswire)
2024-09-19 03:40
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion(Accesswire)
2024-09-18 01:30
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments(Accesswire)
2024-09-16 23:45
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price(Accesswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.